Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: Two cases and review of the literature

Giuseppina Gallucci, Alfredo Tartarone, Carlo Gabriele Tocchetti, Anna Maria Bochicchio, Mariarosa Coccaro, Alba Capobianco, Nicola Maurea, Giuseppina Improta, Angela Zupa, Michele Aieta

Research output: Contribution to journalArticlepeer-review

Abstract

Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalFuture Oncology
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • preeclampsia
  • sunitinib
  • TKI-induced cardiotoxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: Two cases and review of the literature'. Together they form a unique fingerprint.

Cite this